Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia

L. Vráblová, V. Divoký, P. Kořalková, KM. Poláková, E. Kriegová, R. Janská, J. Grohmann, M. Holzerová, T. Papajík, E. Faber

. 2023 ; 24 (3) : . [pub] 20230120

Language English Country Switzerland

Document type Case Reports

Persistent link   https://www.medvik.cz/link/bmc23004540

The treatment outcome in patients with chronic myeloid leukaemia (CML) in blast crisis (BC) is unsatisfactory despite the use of allogeneic stem cell transplantation (ASCT). Moreover, in some patients ASCT is contraindicated, with limited treatment options. We report the case series of two patients with lymphoid BC CML in whom ASCT was not approachable. The first patient developed BC two months after diagnosis in association with dic(7;9)(p11.2;p11.2) and T315I mutation. Blast crisis with central nervous system leukemic involvement and K611N mutation of the SETD2 gene developed abruptly in the second patient five years after ceasing treatment with nilotinib in major molecular response (MMR) at the patient's request. Both underwent one course of chemotherapy in combination with rituximab and imatinib, followed by dasatinib and interferon α (INFα) treatment in the first and dasatinib alone in the second case. Deep molecular response (DMR; MR 4.0) was achieved within a short time in both cases. It is probable that DMR was caused by a specific immune response to CML cells, described in both agents. The challenging medical condition that prompted these case series, and the subsequent results, suggest a re-visit to the use of a combination of well-known drugs as an area for further investigation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004540
003      
CZ-PrNML
005      
20230425171603.0
007      
ta
008      
230418s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms24032050 $2 doi
035    __
$a (PubMed)36768374
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vráblová, Lucia $u Department of Haemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000319984583
245    10
$a Deep Molecular Response Achieved with Chemotherapy, Dasatinib and Interferon α in Patients with Lymphoid Blast Crisis of Chronic Myeloid Leukaemia / $c L. Vráblová, V. Divoký, P. Kořalková, KM. Poláková, E. Kriegová, R. Janská, J. Grohmann, M. Holzerová, T. Papajík, E. Faber
520    9_
$a The treatment outcome in patients with chronic myeloid leukaemia (CML) in blast crisis (BC) is unsatisfactory despite the use of allogeneic stem cell transplantation (ASCT). Moreover, in some patients ASCT is contraindicated, with limited treatment options. We report the case series of two patients with lymphoid BC CML in whom ASCT was not approachable. The first patient developed BC two months after diagnosis in association with dic(7;9)(p11.2;p11.2) and T315I mutation. Blast crisis with central nervous system leukemic involvement and K611N mutation of the SETD2 gene developed abruptly in the second patient five years after ceasing treatment with nilotinib in major molecular response (MMR) at the patient's request. Both underwent one course of chemotherapy in combination with rituximab and imatinib, followed by dasatinib and interferon α (INFα) treatment in the first and dasatinib alone in the second case. Deep molecular response (DMR; MR 4.0) was achieved within a short time in both cases. It is probable that DMR was caused by a specific immune response to CML cells, described in both agents. The challenging medical condition that prompted these case series, and the subsequent results, suggest a re-visit to the use of a combination of well-known drugs as an area for further investigation.
650    _2
$a lidé $7 D006801
650    _2
$a dasatinib $x terapeutické užití $7 D000069439
650    12
$a blastická krize $x farmakoterapie $x genetika $7 D001752
650    _2
$a interferon alfa $x terapeutické užití $7 D016898
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    12
$a chronická myeloidní leukemie $x farmakoterapie $x genetika $7 D015464
655    _2
$a kazuistiky $7 D002363
700    1_
$a Divoký, Vladimír $u Department of Biology, Faculty of Medicine and Dentistry, Palacký University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/000000030202245X $7 xx0018902
700    1_
$a Kořalková, Pavla $u Department of Biology, Faculty of Medicine and Dentistry, Palacký University, 779 00 Olomouc, Czech Republic
700    1_
$a Poláková, Kateřina Machová $u Institute of Haematology and Blood Transfusion, 120 00 Prague, Czech Republic
700    1_
$a Kriegová, Eva $u Department of Immunology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University, 779 00 Olomouc, Czech Republic
700    1_
$a Janská, Romana $u Department of Haemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University, 779 00 Olomouc, Czech Republic
700    1_
$a Grohmann, Jan $u Department of Haemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University, 779 00 Olomouc, Czech Republic
700    1_
$a Holzerová, Milena $u Department of Haemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University, 779 00 Olomouc, Czech Republic
700    1_
$a Papajík, Tomáš $u Department of Haemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University, 779 00 Olomouc, Czech Republic
700    1_
$a Faber, Edgar $u Department of Haemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University, 779 00 Olomouc, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 24, č. 3 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36768374 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171559 $b ABA008
999    __
$a ok $b bmc $g 1924936 $s 1190749
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 24 $c 3 $e 20230120 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options